# Classys Reports Nine-Month 2026 Revenue of KRW 275.7 Billion, Up 13% Year over Year; Prepares to Accelerate Growth in 2027 on China Entry, U.S. and Europe Expansion, New Product Launches and Direct-Operations Integration

- Link: https://www.thailand-business-news.com/pr-news/classys-reports-nine-month-2026-revenue-of-krw-275-7-billion-up-13-year-over-year-prepares-to-accelerate-growth-in-2027-on-china-entry-u-s-and-europe-expansion-new-product-launches-and-direct-ope
- Published: 2026-11-13T14:24:00+07:00
- Author: PR Newswire

◦ Nine-month revenue of KRW 275.7 billion and operating profit of KRW 108.1 billion;
   revenue up 13% year over year
 ◦ China market entry and broader product lineups in the U.S. and Europe strengthen
   the foundation for medium- to long-term growth
 ◦ New devices and cartridges in Korea, together with the stabilization of the LATAM
   and Japan direct-operations subsidiaries, are expected to speed up profitability
   improvement

SEOUL, South Korea, Nov. 13, 2026 /PRNewswire/ — Classys Inc. (KOSDAQ: 214150), 
a global medical aesthetics company, announced on November 12 (KST) its results 
for the third quarter of 2026. On a consolidated basis, nine-month revenue was KRW
275.7 billion and operating profit was KRW 108.1 billion. Revenue increased 13% 
year over year, while operating profit decreased 9.4%. For the third quarter alone,
revenue was KRW 83.0 billion, roughly flat year over year; operating profit was 
KRW 27.0 billion, for an operating margin of 32.5%.

The third quarter was a period in which near-term pressure on results came together:
lower sales in Korea as the Company’s core products entered a generational transition,
and the shift of LATAM and Japan to direct operations. In LATAM, the Company incurred
initial costs to normalize operations at its direct-operations subsidiary, and distribution
margin recognized during the sell-through of inventory held before the acquisition
of Medsystems (now Classys Brasil) was limited. In Japan, upfront investment related
to the transition to direct operations also affected profitability.

The Company views these as temporary integration costs arising from the restructuring
of its global business and a product launch cycle. It expects this pressure to ease
gradually, and plans to accelerate its recovery and global growth through the stabilization
of its direct-operations structure and business expansion in large markets such 
as China. The Company expects its growing cumulative global unit sales, which have
surpassed 50,000 units as of October 2026, along with its accumulated brand, technology
and product strengths and its cash-generating capacity, to support this acceleration.

**China**
Ahead of its first product approval in China, the Company expects growth
momentum in this large market to build. China is becoming a market where companies
must obtain formal regulatory approval as approval barriers rise, and demand is 
expanding mainly for newly approved devices. Classys expects approval of Volnewmer,
its globally successful device, in December, and is in discussions with prospective
large local partners on distribution agreements. The Company also expects approval
of Ultraformer (known as Shurink in Korea) in the first half of 2027 and of its 
new product Viclara in the second half. By broadening the range of products it can
sell in China, the Company plans to respond to a wider range of procedure demand
in stages and pursue faster revenue growth and improved profitability.

**U.S. and Europe**
The U.S., Europe and other regions are large markets with relatively
low penetration and ample room for further growth. In the U.S., the Company is operating
mainly with Everesse (marketed as Volnewmer in Korea) and its new product Quadessy.
It plans to use the customer base built with Everesse to introduce Viclara, Reepot
and Ultraformer in sequence, to expand its product portfolio and accelerate revenue
growth. In Europe, building on the business models confirmed in Spain and Turkey,
the Company plans to actively expand the market with a broader lineup than its competitors,
including Ultraformer and Volnewmer, as well as Quadessy, Viclara and Veloce.

**Korea**
In Korea, the Company has begun full-scale marketing for its new four-
wavelength laser device Fortra, featuring a famous model, and expects Fortra to 
grow alongside Shurink Universe, Volnewmer and Quadessy. In the first half of 2027,
the Company plans to introduce a new procedure protocol and a new Volnewmer tip,
as part of a strategy to grow device and consumables revenue together. It also plans
to launch a new HIFU product with higher output than the existing Shurink Universe,
to strengthen its market leadership.

**Direct-operations –**  **LATM and Japan**
At the LATAM direct-operations subsidiary,
the Company expects a transition to a normal margin structure as the sell-through
of pre-acquisition inventory is completed. It is also making strategic investments
in organizational reinforcement, brand repositioning and B2C marketing, and plans
to expand cross-selling of Volnewmer, Quadessy and laser products to Ultraformer
customers. At the Japan direct-operations subsidiary, the Company plans to expand
its customer base centered on large clinic chains and to accelerate sales of Volnewmer
and Quadessy.

"In the third quarter we faced a weak domestic market and profitability pressure
at our overseas direct-operations subsidiaries, but we continue to secure new growth
opportunities on the strength of more than 50,000 cumulative units sold, including
the largest cumulative HIFU unit sales in the global industry," said CEO Jun-oh 
Yoon. "We have been bringing in new global top-level executives, including Vice 
President and Chief Commercial Officer Jung-hee Bae and Chief Technology Officer
Dr. Taek-Soo Kim, fully reorganized the company around markets and customers, and
completed the operating framework for product innovation and global growth and expansion.
Through China market entry, a broader lineup in the U.S. and Europe, and innovative
new product launches, we aim to accelerate revenue growth, and we will focus on 
improving profitability by normalizing operations at our direct-operations subsidiaries.

**About Classys**

Classys Inc. (KOSDAQ: 214150) is a global medical aesthetics platform company headquartered
in Seoul, South Korea. The Company develops and sells energy-based aesthetic devices,
including HIFU (Ultraformer), monopolar radiofrequency (Volnewmer, marketed as Everesse
in the U.S.), Microneedling RF (Quadessy), and other product lines such as dermabrasion(
Viclara) and laser systems, together with related consumables. Classys serves clinics
in more than 80 countries and has surpassed 50,000 cumulative units sold worldwide
as of October 2026. The Company operates through distribution partners and, in selected
markets such as South America and Japan, through direct-operations subsidiaries.
For more information, visit classys.com. 

 

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Classys Reports Nine-Month 2026 Revenue of KRW 275.7 Billion, Up 13% Year over Year; Prepares to Accelerate Growth in 2027 on China Entry, U.S. and Europe Expansion, New Product Launches and Direct-Operations Integration ](https://en.prnasia.com/story/archive/5097049_CN97049_0?rand=184833)